Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Back to dashboard
Company Information
About this company
Key people
Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Anand Mehra
Independent Director
Vincent J. Milano
Independent Director
Hugh M. Davis
President, Chief Operating Officer, Director
Kevin Balthaser
Chief Financial Officer
Roland Kolbeck
Chief Scientific Officer
Jesse Hall
Chief Medical Officer
James Loerop
Chief Business Officer
Christopher P. Molineaux
Lead Independent Director
Maxine Gowen
Independent Director
William Douglas Humphries
Independent Director
Click to see more
Key facts
- Shares in issue147.20m
- EPICACRS
- ISINUS00461U1051
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$482.81m
- Employees69
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.